{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:28:07Z","timestamp":1791203287111,"version":"4.2.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obsessive-compulsive disorder (OCD) is among the most disabling neuropsychiatric conditions characterized by the presence of repetitive intrusive thoughts, impulses, or images (obsessions) and\/or ritualized mental or physical acts (compulsions). Serotonergic medications, particularly Selective Serotonin Reuptake Inhibitors (SSRIs), are the first-line treatments for patients with OCD. Recently, dysregulation of glutamatergic system has been proposed to be involved in the etiology of OCD. We designed this systematic review and meta-analysis to evaluate clinical efficacy of glutamatergic medications in patients with OCD, according to the guidelines of Cochrane collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We searched Medline, Scopus, and Cochrane library without applying any language filter. Two of the authors independently reviewed search results for irrelevant and duplicate studies and extracted data and assessed methodological quality of the studies. We transformed data into a common rubric and calculated a weighted treatment effect across studies using Review Manager.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 476 references in 3 databases, and after exclusion of irrelevant and duplicate studies, 17 studies with total number of 759 patients with OCD were included. In the present review we found evidence for several drugs such as memantine, N-acetylcysteine (NAC), Minocycline, L-carnosine and riluzole. Glutamaterigic drug plus SSRIs were superior to SSRI+ Placebo with regard to Y-BOCS scale [standardized mean difference (SMD\u2009=\u2009\u2212\u20093.81 95% CI\u2009=\u2009\u2212\u20094.4, \u2212\u20093.23).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Augmentation of glutamatergic medications with SSRIs are beneficial in obsessive-compulsive patients, no harmful significant differences in any safety outcome were found between the groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-021-00534-6","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T13:02:44Z","timestamp":1636030964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Fatemeh","family":"Hadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Kashefinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Kamalzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Hoobehfekr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Shalbafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"534_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae): American Psychiatric Pub","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae): American Psychiatric Pub; 2013."},{"issue":"4","key":"534_CR2","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.19r13085","volume":"81","author":"EJ Fawcett","year":"2020","unstructured":"Fawcett EJ, Power H, Fawcett JM. Women are at greater risk of OCD than men: a meta-analytic review of OCD prevalence worldwide. J Clin Psychiatry. 2020;81(4):0.","journal-title":"J Clin Psychiatry"},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.neubiorev.2017.05.029","volume":"80","author":"VM Sinopoli","year":"2017","unstructured":"Sinopoli VM, Burton CL, Kronenberg S, Arnold PD. A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev. 2017;80:372\u201381. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.05.029.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"534_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.29252\/shefa.7.2.99","volume":"7","author":"M Nabizadeh","year":"2019","unstructured":"Nabizadeh M. The role of serotonin and dopamine neurotransmitters in obsessive-compulsive disorder. Neurosci J Shefaye Khatam. 2019;7(2):99\u2013106. https:\/\/doi.org\/10.29252\/shefa.7.2.99.","journal-title":"Neurosci J Shefaye Khatam"},{"issue":"11","key":"534_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0269881119878177","volume":"33","author":"M Shalbafan","year":"2019","unstructured":"Shalbafan M, Malekpour F, Tadayon Najafabadi B, Ghamari K, Dastgheib S-A, Mowla A, et al. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: a placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019;33(11):1407\u201314. https:\/\/doi.org\/10.1177\/0269881119878177.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"534_CR6","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.4103\/0019-5545.196976","volume":"59","author":"YJ Reddy","year":"2017","unstructured":"Reddy YJ, Sundar AS, Narayanaswamy JC, Math SB. Clinical practice guidelines for obsessive-compulsive disorder. Indian J Psychiatry. 2017;59(Suppl 1):S74. https:\/\/doi.org\/10.4103\/0019-5545.196976.","journal-title":"Indian J Psychiatry"},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/NDT.S211703","volume":"16","author":"S Karthik","year":"2020","unstructured":"Karthik S, Sharma LP, Narayanaswamy JC. Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2020;16:1003\u201313. https:\/\/doi.org\/10.2147\/NDT.S211703.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"534_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/npp.2016.260","volume":"42","author":"J Naaijen","year":"2017","unstructured":"Naaijen J, Zwiers MP, Amiri H, Williams SC, Durston S, Oranje B, et al. Fronto-striatal glutamate in autism spectrum disorder and obsessive compulsive disorder. Neuropsychopharmacology. 2017;42(12):2456\u201365. https:\/\/doi.org\/10.1038\/npp.2016.260.","journal-title":"Neuropsychopharmacology."},{"issue":"22","key":"534_CR9","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.3390\/ijms20225674","volume":"20","author":"S Magi","year":"2019","unstructured":"Magi S, Piccirillo S, Amoroso S, Lariccia V. Excitatory amino acid transporters (EAATs): glutamate transport and beyond. Int J Mol Sci. 2019;20(22):5674. https:\/\/doi.org\/10.3390\/ijms20225674.","journal-title":"Int J Mol Sci"},{"issue":"06","key":"534_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0043-118665","volume":"51","author":"P Vl\u010dek","year":"2018","unstructured":"Vl\u010dek P, Pol\u00e1k J, Brunovsk\u00fd M, Hor\u00e1\u010dek J. Role of glutamatergic system in obsessive-compulsive disorder with possible therapeutic implications. Pharmacopsychiatry. 2018;51(06):229\u201342. https:\/\/doi.org\/10.1055\/s-0043-118665.","journal-title":"Pharmacopsychiatry."},{"key":"534_CR11","doi-asserted-by":"crossref","unstructured":"Hollestein V, Buitelaar JK, Brandeis D, Banaschewski T, Kaiser A, Hohmann S, et al. Developmental changes in fronto-striatal glutamate and their association with functioning during inhibitory control in autism spectrum disorder and obsessive compulsive disorder. NeuroImage Clinical. 2021;30:102622.","DOI":"10.1016\/j.nicl.2021.102622"},{"issue":"2","key":"534_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1017\/S1461145701002401","volume":"4","author":"DR Rosenberg","year":"2001","unstructured":"Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive\u2013compulsive disorder. Int J Neuropsychopharmacol. 2001;4(2):179\u201390. https:\/\/doi.org\/10.1017\/S1461145701002401.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9","key":"534_CR13","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","volume":"30","author":"K Chakrabarty","year":"2005","unstructured":"Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735\u201340. https:\/\/doi.org\/10.1038\/sj.npp.1300733.","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"534_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1038\/npp.2009.77","volume":"34","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar S. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive\u2013compulsive disorder. Neuropsychopharmacology. 2009;34(12):2489\u201396. https:\/\/doi.org\/10.1038\/npp.2009.77.","journal-title":"Neuropsychopharmacology."},{"key":"534_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neubiorev.2015.02.009","volume":"52","author":"J Naaijen","year":"2015","unstructured":"Naaijen J, Lythgoe DJ, Amiri H, Buitelaar JK, Glennon JC. Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2015;52:74\u201388. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.02.009.","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"534_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40501-015-0051-8","volume":"2","author":"C Pittenger","year":"2015","unstructured":"Pittenger C. Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry. 2015;2(3):271\u201383. https:\/\/doi.org\/10.1007\/s40501-015-0051-8.","journal-title":"Curr Treat Options Psychiatry"},{"issue":"3","key":"534_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","volume":"132","author":"C Pittenger","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132(3):314\u201332. https:\/\/doi.org\/10.1016\/j.pharmthera.2011.09.006.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"534_CR18","doi-asserted-by":"publisher","first-page":"e0190593","DOI":"10.1371\/journal.pone.0190593","volume":"13","author":"HW Kim","year":"2018","unstructured":"Kim HW, Kang JI, Hwang EH, Kim SJ. Association between glutamate transporter gene polymorphisms and obsessive-compulsive disorder\/trait empathy in a Korean population. PLoS One. 2018;13(1):e0190593. https:\/\/doi.org\/10.1371\/journal.pone.0190593.","journal-title":"PLoS One"},{"issue":"7","key":"534_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/1570159X15666170320104237","volume":"15","author":"Z Marinova","year":"2017","unstructured":"Marinova Z, Chuang D-M, Fineberg N. Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol. 2017;15(7):977\u201395. https:\/\/doi.org\/10.2174\/1570159X15666170320104237.","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"534_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u2013e34. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.006.","journal-title":"J Clin Epidemiol"},{"issue":"oct18 2","key":"534_CR21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"3","key":"534_CR22","first-page":"234","volume":"30","author":"S Lu","year":"2018","unstructured":"Lu S, Nasrallah HA. The use of memantine in neuropsychiatric disorders: an overview. Ann Clin Psychiatry. 2018;30(3):234\u201348.","journal-title":"Ann Clin Psychiatry"},{"issue":"8","key":"534_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","volume":"26","author":"G Sani","year":"2012","unstructured":"Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias. CNS Drugs. 2012;26(8):663\u201390. https:\/\/doi.org\/10.2165\/11634390-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"2","key":"534_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175\u201380. PubMed PMID: 23063327. Epub 2012\/10\/16. eng. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.09.015.","journal-title":"J Psychiatr Res"},{"issue":"3","key":"534_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.psychres.2013.12.051","volume":"215","author":"M-R Khodaie-Ardakani","year":"2014","unstructured":"Khodaie-Ardakani M-R, Mirshafiee O, Farokhnia M, Tajdini M, Modabbernia A, Rezaei F, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014;215(3):540\u20136. https:\/\/doi.org\/10.1016\/j.psychres.2013.12.051.","journal-title":"Psychiatry Res"},{"issue":"1","key":"534_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/YIC.0000000000000098","volume":"31","author":"H Emadi-Kouchak","year":"2016","unstructured":"Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A, Rasoulinejad M, Zeinoddini A, Yalda A, et al. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol. 2016;31(1):20\u20136. https:\/\/doi.org\/10.1097\/YIC.0000000000000098.","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"534_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/pcn.12430","volume":"70","author":"S Esalatmanesh","year":"2016","unstructured":"Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan MR, et al. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive\u2013compulsive disorder: a placebo-controlled, double-blind, randomized trial. Psychiatry Clin Neurosci. 2016;70(11):517\u201326. https:\/\/doi.org\/10.1111\/pcn.12430.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"534_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.freeradbiomed.2009.12.021","volume":"48","author":"Y Shen","year":"2010","unstructured":"Shen Y, He P, Fan Y-y, Zhang J-x, Yan H-j, Hu W-w, et al. Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. Free Radic Biol Med. 2010;48(5):727\u201335. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2009.12.021.","journal-title":"Free Radic Biol Med"},{"key":"534_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.psychres.2018.02.012","volume":"262","author":"A Ghajar","year":"2018","unstructured":"Ghajar A, Khoaie-Ardakani M-R, Shahmoradi Z, Alavi A-R, Afarideh M, Shalbafan M-R, et al. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Psychiatry Res. 2018;262:94\u2013101. https:\/\/doi.org\/10.1016\/j.psychres.2018.02.012.","journal-title":"Psychiatry Res"},{"key":"534_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jad.2020.02.020","volume":"267","author":"B Araminia","year":"2020","unstructured":"Araminia B, Shalbafan M, Mortezaei A, Shirazi E, Ghaffari S, Sahebolzamani E, et al. L-carnosine combination therapy for major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2020;267:131\u20136. https:\/\/doi.org\/10.1016\/j.jad.2020.02.020.","journal-title":"J Affect Disord"},{"issue":"4","key":"534_CR31","doi-asserted-by":"publisher","first-page":"e2584","DOI":"10.1002\/hup.2584","volume":"32","author":"S Arabzadeh","year":"2017","unstructured":"Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: a randomized double-blind study. Hum Psychopharmacol Clin Exp. 2017;32(4):e2584. https:\/\/doi.org\/10.1002\/hup.2584.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"534_CR32","first-page":"CD001447","volume":"2","author":"RG Miller","year":"2000","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2000;2:CD001447 PubMed PMID: 10796796. Epub 2000\/05\/05. eng.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"534_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/pcn.12394","volume":"70","author":"S Emamzadehfard","year":"2016","unstructured":"Emamzadehfard S, Kamaloo A, Paydary K, Ahmadipour A, Zeinoddini A, Ghaleiha A, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive\u2013compulsive disorder: R andomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2016;70(8):332\u201341. https:\/\/doi.org\/10.1111\/pcn.12394.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"534_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.4088\/JCP.14m09123","volume":"76","author":"C Pittenger","year":"2015","unstructured":"Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, et al. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(8):1075\u201384. PubMed PMID: 26214725. Pubmed Central PMCID: PMC4560666. Epub 2015\/07\/28. eng. https:\/\/doi.org\/10.4088\/JCP.14m09123.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"534_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn.100057","volume":"36","author":"O Dean","year":"2011","unstructured":"Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011;36(2):78\u201386. https:\/\/doi.org\/10.1503\/jpn.100057.","journal-title":"J Psychiatry Neurosci"},{"issue":"6","key":"534_CR36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","volume":"32","author":"H Afshar","year":"2012","unstructured":"Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32(6):797\u2013803. https:\/\/doi.org\/10.1097\/JCP.0b013e318272677d.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"534_CR37","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4088\/JCP.16m11101","volume":"78","author":"DL Costa","year":"2017","unstructured":"Costa DL, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, et al. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2017;78(7):0.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"534_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/jcpt.12370","volume":"41","author":"K Paydary","year":"2016","unstructured":"Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive\u2013compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2016;41(2):214\u20139. https:\/\/doi.org\/10.1111\/jcpt.12370.","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"534_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","volume":"29","author":"J Sarris","year":"2015","unstructured":"Sarris J, Oliver G, Camfield DA, Dean OM, Dowling N, Smith DJ, et al. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs. 2015;29(9):801\u20139. https:\/\/doi.org\/10.1007\/s40263-015-0272-9.","journal-title":"CNS Drugs"},{"issue":"1","key":"534_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nurx.2005.12.006","volume":"3","author":"C Pittenger","year":"2006","unstructured":"Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):69\u201381. https:\/\/doi.org\/10.1016\/j.nurx.2005.12.006.","journal-title":"NeuroRx."},{"issue":"4","key":"534_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1089\/cap.2010.0009","volume":"20","author":"P Grant","year":"2010","unstructured":"Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2010;20(4):309\u201315. https:\/\/doi.org\/10.1089\/cap.2010.0009.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl 1","key":"534_CR42","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.4103\/psychiatry.IndianJPsychiatry_520_18","volume":"61","author":"K Sheshachala","year":"2019","unstructured":"Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive\u2013compulsive disorder. Indian J Psychiatry. 2019;61(Suppl 1):S58\u201365. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_520_18.","journal-title":"Indian J Psychiatry"},{"issue":"4","key":"534_CR43","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","volume":"100","author":"K Wu","year":"2012","unstructured":"Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive\u2013compulsive disorder. Pharmacol Biochem Behav. 2012;100(4):726\u201335. https:\/\/doi.org\/10.1016\/j.pbb.2011.10.007.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"534_CR44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1017\/S1461145711001829","volume":"15","author":"NA Fineberg","year":"2012","unstructured":"Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012;15(8):1173\u201391. https:\/\/doi.org\/10.1017\/S1461145711001829.","journal-title":"Int J Neuropsychopharmacol"},{"key":"534_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1875397300802010062","volume":"2","author":"JT Ting","year":"2008","unstructured":"Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chemical Genomics. 2008;2:62\u201375. https:\/\/doi.org\/10.2174\/1875397300802010062.","journal-title":"Curr Chemical Genomics"},{"key":"534_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/PRBM.S58601","volume":"8","author":"MA Grados","year":"2015","unstructured":"Grados MA, Atkins EB, Kovacikova GI, McVicar E. A selective review of glutamate pharmacological therapy in obsessive\u2013compulsive and related disorders. Psychol Res Behav Manag. 2015;8:115. https:\/\/doi.org\/10.2147\/PRBM.S58601.","journal-title":"Psychol Res Behav Manag"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-021-00534-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-021-00534-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T13:02:58Z","timestamp":1636030978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-021-00534-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s40360-021-00534-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"5 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the type of article (Review), there was no need for obtaining ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}